• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Advanced Plant Pharmaceuticals Rated 'Speculative Buy,' Target Price $0.06 By Beacon Equity Research

Posted on: Friday, 2 February 2007, 18:01 CST

Advanced Plant Pharmaceuticals (OTCBB:APPI) has been rated "Speculative Buy" with a target price of $0.06 by Beacon Equity Research Analyst Dr. Victor Sula.

The full report is available at http://www.BeaconEquityResearch.com.

Anyone interested in receiving alerts regarding Advanced Plant Pharmaceuticals research should email members@beaconequityresearch.com with "APPI" in the subject line.

In the report, Dr. Sula writes, "Advanced Plant Pharmaceuticals, Inc. is shifting its business plan to focus on biofuels and renewable energy production and distribution. In Q4FY06, APPI announced an agreement to acquire World Health Energy (WHE), a renewable energy company focused on the development and production of alternative fuels. WHE plans to use cost-effective agricultural products both locally and from around the world to develop natural alternative fuels. The Company plans to build two biodiesel plants in the US and is in the process of securing financing for their construction."

"According to Clean Edge research, the global biofuels market will grow from $15.7 billion in 2005 to $52.5 billion by 2015. Meanwhile, Emerging Markets Online forecasts US biodiesel consumption will grow to 750 million gallons by the end of 2007. Moreover, the US biodiesel market should grow significantly to match the consumption levels of European counterparts. Total biodiesel sales in the US amounted to less than 0.5% of all petro-diesel on-road consumption in 2005."

"We believe the Company's market capitalization and valuation will gravitate towards its bio-fuel peers. Many early-stage bio-fuel companies are trading at huge premiums to other industry medians. Competitors such as Earth Biofuels (OTCBB:EBOF), Pacific Ethanol (Nasdaq:PEIX), Verasun Energy (NYSE:VSE) and Southridge Ethanol (OTCBB:SORD) trade at a P/S multiple of roughly 10 or less."

Beacon Equity Research Disclosure

The analysts contributing to this report do not hold any shares of Advanced Plant Pharmaceuticals (APPI). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research ("Beacon") certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon has directly been compensated seven thousand five hundred dollars by Oceanic Consulting for enrollment in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.

Source: Business Wire

More News in this Category